Chemokine receptor-dependent alloresponses

Immunological Reviews

Volumn 196, Issue , 2003, Pages 37-50

  Hancock, Wayne W ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; RANTES; TUMOR NECROSIS FACTOR;

ACUTE GRAFT REJECTION; ALLOGRAFT; ALLOIMMUNITY; ANTIGEN PRESENTATION; B LYMPHOCYTE; BRAIN DEATH; CELL ACTIVITY; CELL DESTRUCTION; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL MOTION; CHRONIC GRAFT REJECTION; DENDRITIC CELL; DONOR; DRUG TARGETING; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INJURY; KIDNEY TRANSPLANTATION; LEUKOCYTE; LIVER TRANSPLANTATION; LYMPHOID TISSUE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL MOVEMENT; CYTOKINES; HUMANS; ISOANTIGENS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 0344121833     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-065X.2003.00084.x     Document Type: Review

References (97)

1. Bergese SD, Pelletier RP, Ferguson RM, Orosz CG. Graft endothelial VCAM-1 is not necessary for acute cardiac allograft rejection in mice. Transplant Proc 1995;27:480-481.
2. Schwarz C, Regele H, Steininger R, Hansmann C, Mayer G, Oberbauer R. The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction. Transplantation 2001;71: 1666-1670.
3. Lacha J, et al. Intercellular cell adhesion molecule-1 and selectin ligands in acute cardiac allograft rejection: a study on gene-deficient mouse models. J Leukoc Biol 2002;71:311-318.
4. Murphy PM, et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176.
5. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002;54:227-229.
6. Power CA. Knockout models to dissect chemokine receptor function in vivo. J Immunol Methods 2003;273:73-82.
7. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990;171:307-314.
8. Hancock WW, Wang L, Ye Q. Chemokine-directed dendritic cell trafficking in allograft rejection. Curr Opin Organ Transplant 2003;8:35-39.
9. Forster R, et al. CCR7 coordinates the primary immune response by establishing functional microenvironrnents in secondary lymphoid organs. Cell 1999;99:23-33.
10. Gunn MD, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189: 451-460.
11. Starzl TE, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992;340:876-877.
12. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
13. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447-450.
14. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-2102.
15. Sozzani S, Allavena P, Vecchi A, Mantovani A. The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol 1999;66:1-9.
16. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000;12: 511-516.
17. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-336.
18. Cecka JM. Kidney transplantation from living unrelated donors. Annu Rev Med 2000;51:393-406.
19. Pratschke J, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999;67:343-348.
20. Kahn J. Stripped for parts. Wired 2003;3:132-136.
21. van der Hoeven JA, et al. Induction of organ dysfunction and up-regulation of inflammatory markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors. Transplantation 1999;68:1884-1890.
22. Pahl HL. Activators and target genes of Rel/ NF-κB transcription factors. Oncogene 1999;18:6853-6866.
23. Takada M, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998;65:1533-1542.
24. Kusaka M, et al. Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation 2000;69: 405-410.
25. Wilhelm MJ, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000;102:2426-2433.
26. Pratschke J, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001;12: 2474-2481.
27. Gasser M, et al. Normalization of brain death-induced injury to rat renal allografts by recombinant soluble P-selectin glycoprotein ligand. J Am Soc Nephrol 2002;13:1937-1945.
28. Pratschke J, et al. Improvements in early behavior of rat kidney allografts after treatment of the brain-dead donor. Ann Surg 2001;234:732-740.
29. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998;4:1392-1396.
30. Yet SF, et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001;89:168-173.
31. Cecka JM, Shoskes DA, Gjertson DW. Clinical impact of delayed graft function for kidney transplantation. Transplant Rev 2001;15:57-65.
32. Heinzelmann M, Mercer-Jones MA, Passmore JC. Neutrophils and renal failure. Am J Kidney Dis 1999;34:384-399.
33. Martinez-Mier G, Toledo-Pereyra LH, McDuffie JE, Warner RL, Ward PA. P-Selectin and chemokine response after liver ischemia and reperfusion. J Am Coll Surg 2000;191:395-402.
34. Tarzami ST, Cheng R, Miao W, Kitsis RN, Berman JW. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J Mol Cell Cardiol 2002;34: 209-221.
35. Yan SF, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-1361.
36. Okada M, et al. Extinguishing Egr-1-dependent inflammatory and thrombotic cascades after lung transplantation. FASEB J 2001;15:2757-2759.
37. Krishnadasan B, et al. Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus. J Thorac Cardiovasc Surg 2002;123:756-767.
38. Naidu BV, et al. Regulation of chemokine expression by cyclosporine A in alveolar macrophages exposed to hypoxia and reoxygenation. Ann Thorac Surg 2002;74:899-905 (Discussion, 905).
39. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 1998;27:1172-1177.
40. Martinez-Mier G, Toledo-Pereyra LH, McDuffie E, Warner RL, Ward PA. L-Selectin and chemokine response after liver ischemia and reperfusion. J Surg Res 2000;93: 156-162.
41. Kataoka M, et al. Effect of cold-ischemia time on c-x-c chemokine expression and neutrophil accumulation in the graft liver after orthotopic liver transplantation in rats. Transplantation 2002;73:1730-1735.
42. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nudear factor-κB and induces neutrophil infiltration via lipopolysaccharide-induced cxc chemokine. Circulation 2001;103:2296-2302.
43. Lakshminarayanan V, et al. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001;159:1301-1311.
44. Nossuli TO, et al. Brief murine myocardial I/R induces chemokines in a TNF-α-independent manner: role of oxygen radicals. Am J Physiol Heart Circ Physiol 2001;281:H2549-H2558.
45. Lemay S, Rabb H, Postler G, Singh AK. Prominent and sustained up-regulation of gp130-signaling cytokines and of the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 2000;69:959-963.
46. Sung PL, Zhu TY, Au-Yeung KK, Siow YL, OK. Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-κB. Kidney Int 2002;62:1160-1170.
47. Oz MC, et al. Ischemia-induced interleukin-8 release after human heart transplantation. A potential role for endothelial cells. Circulation 1995;92:II428-II432.
48. Kukielka GL, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995;95:89-103.
49. Kumar AG, et al. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation 1997;95:693-700.
50. Miura M, Fu X, Zhang QW, Remick DG, Fairchild RL. Neutralization of Gro-α and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 2001;159:2137-2145.
51. Ono K, et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999;79:195-203.
52. Frangogiannis NG, Mendoza LH, Lewallen M, Michael LH, Smith CW, Entman ML. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J 2001;15:1428-1430.
53. Wang D, Sai J, Richmond A. Cell surface heparan sulfate participates in CXCL1-induced signaling. Biochemistry 2003;42:1071-1077.
54. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001;193:975-980.
55. Hancock WW, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000;192:1515-1519.
56. + T cell activation. Genes Cells 2002;7:309-320.
57. +-ATPase activity in an immortalized human proximal tubule cell line. J Immunol 2003;170:931-940.
58. Lasagni L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-1549.
59. Gao W, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001;72:1199-1205.
60. Gao W, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000;105:35-44.
61. Haskell CA, et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001;108:679-688.
62. Robinson LA, et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-6072.
63. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (cx3cr1) in human kidney diseases. Kidney Int 2002;62: 488-495.
64. Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002;11:332-338.
65. Hancock WW, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993;56:643-650.
66. Grone HJ, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999;13:1371-1383.
67. Song E, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002;61:676-685.
68. Proudfoot AE, Power CA, Rommel C, Wells TN. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003;15: 57-65.
69. Yun JJ, et al. The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am J Pathol 2002;161:1307-1313.
70. Kobayashi H, Novick AC, Toma H, Fairchild RL. Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts. Transplantation 2002;74:387-395.
71. Belperio JA, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002;169:1037-1049.
72. Belperio JA, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001;108:547-556.
73. Melter M, Exeni A, Briscoe DM. Chemokines and their receptors in human clinical solid organ transplantation. Curr Opin Organ Transplant 2002;7:77-84.
74. Segerer S, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001;37:518-531.
75. Agostini C, et al. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001;158:1703-1711.
76. Goddard S, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001;72:1957-1967.
77. Melter M, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001;104:2558-2564.
78. Zhao DXM, Hu YY, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFN-γ-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002;169:1556-1560.
79. Fahmy NM, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003;75:72-78.
80. + activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant (in press).
81. Akalin E, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001;72:948-953.
82. Miura M, et al. Monokine induced by IFN-γ is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001;167:3494-3504.
83. Koga S, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-γ-induced chemokine Mig. J Immunol 1999;163:4878-4885.
84. Li BG, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001;344:947-954.
85. Akalin E, Murphy B. Gene polymorphisms and transplantation. Curr Opin Immunol 2001;13:572-576.
86. Hancock WW. Chemokines and transplant immunobiology. J Am Soc Nephrol 2002;13:821-824.
87. Fischereder M, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;357:1758-1761.
88. Sullivan JS. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;358:1269-1270.
89. Abdi R, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002;13:754-758.
90. Geraghty DE, Daza R, Williams LM, Vu Q, Ishitani A. Genetics of the immune response: identifying immune variation within the MHC and throughout the genome. Immunol Rev 2002;190:69-85.
91. Daly AK, Day CP, Donaldson PT. Polymorphisms in immunoregulatory genes: towards individualized immune suppressive therapy? Am J Pharmacogenomics 2002;2:13-23.
92. Ozkaynak E, et al. Importance ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001;2:591-596.
93. Ye Q, et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002;195:795-800.
94. Ozkaynak E, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002;169:6546-6553.
95. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFκB: Implications for tolerance induction. Transplantation 2000;70:415-419.
96. Bowdish ME, et al. Evaluation of an oral CXCR3 antagonist in a rat model of acute cardiac allograft rejection. J Heart Lung Transplant 2003;22:S162.
97. Gao P, et al. The unique target specificity of a nonpeptide chemokine receptcr antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 2003;73:273-280.